The earnings season for the drug/biotech sector is now in its final lap, with two S&P 500 companies, Viatris (VTRS) and Perrigo Company (PRGO) , and some other drug/generic companies due to report their first-quarter 2024 results this week.The majority of the large drugmakers have already reported their results. Many of these companies beat estimates for both earnings and sales. Some companies also raised their guidance for 2024, mainly the earnings per share outlook.Per the Zacks classification, the pharma ...